Vaginal estrogen: for dryness, pain with sex and urinary symptoms

Vaginal estrogen is low-dose estradiol used inside the vagina, as a cream, an insert or a ring, for dryness, burning, pain with sex and some urinary symptoms after menopause. Very little reaches the bloodstream, and the Menopause Society does not recommend adding progesterone to low-dose vaginal estrogen. FDA-approved cream, insert and ring products exist. A physician decides.

Prescription. FDA-approved forms exist; ask whether yours is oneVaginal cream, insert or ring

See if hormone therapy is right for me →

Care is provided by Beluga Health, P.A., a physician group licensed in all 50 states and DC.

What vaginal estrogen costs at VevaMD

  • There is no separate price for vaginal estrogen: VevaMD prices hormone therapy by need, not by form.
  • As low as $40/mo, billed $119 every 3 months.
  • Full refund if not prescribed.

Compounded medications are prepared by state-licensed pharmacies for individual patients. They are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality.

Who it may be for, and who should ask first

May be for

  • Women with vaginal dryness, burning, irritation or pain with sex from menopause (vulvar and vaginal atrophy) [1] [2]
  • Women whose only symptoms are vaginal: estrogen labels advise considering a vaginal product first when vaginal symptoms are the only reason for treatment [3]
  • Women already on estrogen for hot flashes whose vaginal symptoms persist

Ask first, or not for

  • Anyone with unexplained vaginal bleeding, which needs to be checked first [1]
  • Women with a history of breast cancer, especially those on an aromatase inhibitor: the decision is made with their oncologist after non-hormonal options [4] [5]

How it works

Low estrogen thins and dries the tissue of the vagina and the urethra, a group of changes called genitourinary syndrome of menopause. Estrogen placed in the vagina acts on that tissue directly. The Menopause Society calls low-dose vaginal estrogen an effective treatment for moderate to severe symptoms, and says the low-dose tablet, insert and ring keep blood estradiol within the postmenopausal range, similar to placebo [6].

Cream, insert or ring

FDA-approved forms of vaginal estradiol
FormExampleWorth knowing
CreamEstrace® vaginal cream [1]Placed in the vagina with an applicator; the amount is set by your physician
Insert (tablet)Vagifem® [2]A small pre-measured insert
RingEstring® [7]A soft ring that stays in place for about three months

Vaginal estrogen is a physician’s choice tied to your answers about vaginal and urinary symptoms; you do not pick a product.

How long it takes

  1. Week 12The insert’s trial measured relief of the most bothersome symptoms at week 12 [2], and the ring’s trials compared vaginal symptoms after 12 weeks [7].
  2. Beyond a yearEndometrial safety has not been studied in clinical trials beyond one year, so persistent use is reviewed with your physician [6].

Side effects and risks

  • Insert: back pain, vulvar or vaginal itching, vaginal yeast infections and diarrhea were the most common side effects (5% or more) [2].
  • Ring: increased vaginal secretions was the most frequent side effect; in trials, headache was reported by 13%, discharge by 7% and a yeast infection by 6% [7].
  • Whole-body risks listed on systemic estrogen labels are highly unlikely with low-dose vaginal estrogen, given how little is absorbed [6].
  • After breast cancer: in a Danish cohort of 8,461 women, vaginal estrogen was not linked to recurrence overall, but it was in women taking an aromatase inhibitor (relative risk 1.39) [8]. Read can I take HRT after breast cancer?.

What the FDA changed

The FDA asked vaginal estrogen labels to drop the heart disease, breast cancer and probable dementia language from the boxed warning, and to condense their safety information to what matters for a local product [9]. Estring® was among the first six relabeled products, on February 12, 2026, and its current label has no boxed warning [10] [7]. On October 23, 2026, the Estrace® cream and Vagifem® labels on DailyMed still carried the older box [1] [2]. The dated record is in the FDA label change tracker.

Is VevaMD’s vaginal estrogen FDA-approved?

VevaMD’s pharmacies fill an estradiol vaginal cream and a vaginal insert in the strengths FDA-approved products come in, and a second vaginal cream compounded at a strength the FDA has not approved, which is not FDA-approved. The pharmacies have not confirmed in writing which products are FDA-approved, so we do not call any of them FDA-approved. Ask your physician which one you receive.

Common questions

Do I need progesterone with vaginal estrogen?

Usually not. The Menopause Society does not recommend a progestogen with low-dose vaginal estrogen, because so little reaches the uterus. Report any bleeding to your physician.

Can I use vaginal estrogen with an estrogen patch or pill?

Yes, if vaginal symptoms persist on systemic estrogen, a physician may add a vaginal form. Your price does not change with the form.

Does vaginal estrogen help with urinary symptoms?

It is a treatment for genitourinary syndrome of menopause, which includes some urinary symptoms such as urgency and discomfort. A physician checks for an infection first.

A physician decides what fits you

See if hormone therapy is right for me →

A private online intake. You see your price before you pay, and your first payment is refunded in full if nothing is prescribed.

Sources

  1. Estrace® (estradiol vaginal cream, USP, 0.01%) prescribing information. Allergan. DailyMed. Checked October 23, 2026.
  2. Vagifem® (estradiol vaginal inserts) prescribing information. Novo Nordisk. DailyMed. Checked October 23, 2026.
  3. Estradiol tablets, USP, prescribing information (Teva; label revised February 2024, before the relabeling). DailyMed. Checked October 23, 2026.
  4. The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767-794. Checked October 23, 2026.
  5. National Institute for Health and Care Excellence (NICE). Menopause: identification and management (NG23). Recommendations, updated April 2026. Checked October 23, 2026.
  6. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. Checked October 23, 2026.
  7. Estring® (estradiol vaginal ring) prescribing information, 2026 revision. Pfizer. DailyMed. Checked October 23, 2026.
  8. Cold S, Cold F, Jensen MB, et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347-1354. Checked October 23, 2026.
  9. FDA. FDA requests labeling changes related to safety information to clarify benefit/risk considerations (menopausal hormone therapy). November 10, 2025; updated February 12, 2026. Checked October 23, 2026.
  10. FDA. Menopausal hormone therapies with updated prescribing information (content current as of February 12, 2026). Checked October 23, 2026.

Last updated October 23, 2026. Content standards

Care is provided by Beluga Health, P.A., a physician group licensed in all 50 states and DC. Clinical care is provided by board-certified, US-licensed physicians. VevaMD Inc is a technology and marketing storefront only — not a medical provider or a pharmacy. Prescriptions are only issued if a licensed physician determines treatment is appropriate. Compounded medications are prepared by state-licensed pharmacies for individual patients. They are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality. This page is general information, not medical advice, and does not replace a visit with your own physician. Brand names are trademarks of their owners; VevaMD is not affiliated with them. Outcomes differ from person to person. Report a side effect to FDA MedWatch.